Latest Analysis

1,840 tickers · updated regularly
Ranks this page's recent reports by score.
HNI Corporation
HNI·Consumer Discretionary
B ★★★Hold
Current$48.31
Target$61.20
Return+26.7%
Nov 6, 2026

HNI offers an earnings-growth opportunity through Steelcase synergies, manufacturing efficiency, and a modest forward valuation, but acquisition-related leverage, dilution, and cyclical furniture demand limit near-term conviction.

Score
70
Navitas Semiconductor Corporation
NVTS·Technology
F Avoid
Current$7.86
Nov 6, 2026

Navitas could benefit from accelerating AI infrastructure power demand through its GaN, SiC, and IVR technologies, but substantial dilution, negative cash flow, and demanding valuation expectations undermine the near-term investment case.

Score
44
CVR Energy, Inc.
CVI·Energy
C ★★Sell
Current$39.84
Nov 6, 2026

CVR Energy offers low standalone valuation multiples and substantial refining expansion potential, but acquisition financing, shareholder dilution, and cyclical margins threaten sustainable per-share value creation.

Score
57
Louisiana-Pacific Corporation
LPX·Industrials
C ★★Sell
Current$76.97
Nov 6, 2026

Louisiana-Pacific's differentiated SmartSide franchise offers long-term market-share and margin potential, but persistent OSB losses, weak free cash flow, and demanding valuation constrain near-term investment attractiveness.

Score
56
Amneal Pharmaceuticals, Inc.
AMRX·Healthcare
D ★Strong Sell
Current$19.45
Nov 6, 2026

Amneal's expanding biosimilar and specialty portfolio supports long-term earnings growth, but elevated valuation, acquisition-related leverage, and weak cash conversion create substantial downside risk.

Score
46
Red Rock Resorts, Inc.
RRR·Consumer Discretionary
D ★Strong Sell
Current$47.96
Nov 6, 2026

Red Rock Resorts benefits from a defensible Las Vegas locals casino franchise and new development opportunities, but expensive valuation, elevated leverage, and weak free cash flow limit its near-term investment appeal.

Score
51
JBT Marel Corporation
JBTM·Industrials
B ★★★Hold
Current$126.82
Target$147.20
Return+16.1%
Nov 6, 2026

JBT Marel can compound earnings through food processing automation, aftermarket services, and merger synergies, but cyclical equipment demand, acquisition debt, and weak consolidated ROIC limit conviction.

Score
74
Alkermes plc
ALKS·Healthcare
C ★★Sell
Current$44.54
Nov 6, 2026

Alkermes could build a stronger neuroscience franchise through LUMRYZ and alixorexton, but acquisition leverage, weak cash conversion, and uncertain clinical returns limit its current investment appeal.

Score
55
Corcept Therapeutics Incorporated
CORT·Healthcare
B ★★★Hold
Current$71.63
Target$92.40
Return+29.0%
Nov 6, 2026

Corcept's rapidly scaling Lifyorli franchise and profitable endocrine business create substantial growth potential, but regulatory uncertainty and dependence on ambitious future earnings expansion limit the margin of safety.

Score
72
Pinnacle West Capital Corporation
PNW·Utilities
C ★★Sell
Current$103.83
Nov 6, 2026

Pinnacle West benefits from a protected Arizona utility franchise and accelerating industrial electricity demand, but premium valuation, heavy capital spending, and regulatory recovery uncertainty constrain shareholder upside.

Score
56
Regal Rexnord Corporation
RRX·Industrials
B ★★★Hold
Current$160.30
Target$191.85
Return+19.7%
Nov 6, 2026

Regal Rexnord combines durable industrial power transmission franchises with fast-growing automation and data-center exposure, but high leverage, weak ROIC, and uneven cash conversion constrain its near-term investment appeal.

Score
68